In a recent SEC filing, Greenwich LifeSciences, Inc. (NASDAQ:GLSI) disclosed that its CEO and CFO, Snehal Patel, acquired 2,000 shares of the company’s common stock. This transaction, which took place on January 2, 2025, was executed at a price of $11.97 per share, for a total of $23,940. The stock has since shown strong momentum, gaining over 18% last week to trade at $12.88. InvestingPro The analysis indicates high volatility in the stock price, with shares trading between $8 and $21.44 over the past 52 weeks. Following this purchase, Patel owns a total of 5,543,702 shares directly, representing a significant portion of the company’s $169.3 million market capitalization. This move reflects Patel’s continued investment in the pharmaceutical company, which specializes in developing new therapies. InvestingPro The data reveals that the company maintains strong liquidity with a current ratio of 6.91, although subscribers can access 7 additional key insights about its financial health and market position in GLSI.

In other recent news, Greenwich LifeSciences reported key results from its Annual Meeting of Stockholders. Significant developments include the re-election of all five director nominees, David McWilliams, Snehal S. Patel, Eric Rothe, F. Joseph Daugherty, MD, and Kenneth Hallock, who each received more than 7.8 million votes. The company’s independent registered public accounting firm, RBSM, LLP, has also been approved for the fiscal year ending December 31, 2024.

An important change to the company’s 2019 Equity Incentive Plan was approved, increasing the number of shares reserved for issuance under the plan from 1,500,000 to 4,000,000. This proposal received more than 8 million votes in favor, indicating strong shareholder support. According to InvestingPro, the company maintains a strong liquidity position, which is shown by a current ratio of 6.91.

Despite its current earnings, Greenwich LifeSciences has been given a promising price target of $38 by analysts, suggesting a potential upside. These recent developments underscore the confidence of shareholders in the company’s current leadership and strategic initiatives.

This article was created with the support of AI and reviewed by an editor. For more information see our T&C.